This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.

This English version is intended to be a reference material to provide convenience for users.

In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of PRECAUTIONS

Potassium iodide (powders, pills)
(preparations indicated for prevention/reduction of internal exposure
of the thyroid gland to radioactive iodine)

December 17, 2024

Therapeutic category

Mineral preparations

Non-proprietary name

Potassium iodide (powders, pills) (preparations indicated for prevention/reduction of internal exposure of the thyroid gland to radioactive iodine)

Safety measure

PRECAUTIONS should be revised.

2. CONTRAINDICATIONS (This drug is contrain	ndicated to the following
patients.)	

Current

<Common to all indications>

Patients receiving eplerenone (for hypertension) or esaxerenone

10. INTERACTIONS

10.1 Contraindications for Co-administration (Do not co-administer with the following.)

Drugs	Signs, symptoms, and treatment	Mechanism/risk factors	
Eplerenone (for hypertension) Esaxerenone	Serum potassium levels may increase.	Potassium retention effect may be enhanced due to coadministration.	

10.2 Precautions for Co-administration (This drug should be administered with caution when co-administered with the following.)

Drugs, etc.	Signs, symptoms, and treatment	Mechanism/risk factors
Eplerenone (for chronic cardiac failure) Finerenone		Potassium retention effect may be enhanced.

Revision 2. CONTRAINDICATIONS (This drug is contraindicated to the following

<Indications other than prevention/reduction of internal exposure of the thyroid gland to radioactive iodine>

Patients receiving eplerenone (for hypertension) or esaxerenone

10. INTERACTIONS

patients.)

10.1 Contraindications for Co-administration (Do not co-administer with the following.)

<Indications other than prevention/reduction of internal exposure of the thyroid gland to radioactive iodine>

Drugs	Signs, symptoms, and treatment	Mechanism/risk factors
Eplerenone (for hypertension) Esaxerenone	Serum potassium levels may increase.	Potassium retention effect may be enhanced due to coadministration.

10.2 Precautions for Co-Administration (This drug should be administered with caution when co-administered with the following.) <Common to all indications>

Drugs	Signs, symptoms, and treatment	Mechanism/risk factors
Eplerenone (for chronic cardiac failure) Finerenone	Serum potassium levels may increase. Careful attention should be paid such	Potassium retention effect may be enhanced.

	as monitoring serum potassium levels periodically.		as monitoring serum potassium levels periodically.	
(N/A)		<pre><prevention pre="" red<=""> <pre>radioactive iodin</pre></prevention></pre>	uction of internal exposure	e of the thyroid gland to
		<u>Drugs</u>	Signs, symptoms, and treatment	Mechanism/risk factors
		Eplerenone (hypertension) Esaxerenone	Serum potassium levels may increase.	Potassium retention effect may be enhanced.

(N/A) Not Applicable. No corresponding language is included in the current PRECAUTIONS.